Glucagon-like peptide-1 receptor agonists as adjunctive treatment for type 1 diabetes: Renewed opportunities through tailored approaches
In virtually all cases, treatment failure relates to the infection itself, not the concurrent medication
GLP-1s, which have been used for years to treat Type 2 diabetes, have gained widespread attention as a way to lose weight and reduce obesity-related conditions and their long-term costs
A broader review in PMC also discusses BPC-157 as a stable gastric pentadecapeptide with substantial preclinical literature across skin wounds, burns, fistulas, tendon, ligament, muscle, bone, nerve, and blood vessel healing models
N Engl J Med 362(4):329344